In The News (Full Edition)

Cells can remain functional despite damage to mitochondria

Mitochondria are the power plants of our cells and play an important role in providing energy for normal function of the tissues in our body. Thanks to a metabolic adjustment, cells can remain functional despite damage to the mitochondria...

Parkinson's

2020-08-31

Cells can remain functional despite damage to mitochondria
Patients’ Diets Need Monitoring for Balance and Levodopa Use, Study Finds

The diets of people with Parkinson’s disease  mostly match those of the general population, but a large portion consume inadequate levels of vitamin D, vitamin B1, zinc, and iron, a Belgian study based on patient questionnaires and dietary pattern records found.


Fewer than 20% of these patients were taking their levodopa medication outside of meals, despite nearly two-thirds being aware that food proteins can affect how this treatment is absorbed by the body.


Investigators advise patients’ eating habits be regularly monitored, and professional guidance be given to improve their diets and better manage their symptoms...

Parkinson's

2020-08-18

Patients’ Diets Need Monitoring for Balance and Levodopa Use, Study Finds
Deep Brain Stimulation Not Linked to Greater Risk of Dementia for Parkinson’s Patients, Study Concludes

Long-term deep brain stimulation (DBS) is cognitively safe and does not increase the risk for dementia in people with Parkinson’s disease, according to the results of a 10-year follow up study.


However, being male, older, having hallucinations, scoring low on cognitive tests, and perioperative cerebral hemorrhage (bleeding in the brain that occurs during or after surgery) were identified as risk factors for developing dementia in Parkinson’s patients with longstanding DBS.


“These results are very encouraging for people with Parkinson’s and their families that they can take advantage of the benefits of deep brain stimulation without worrying about it increasing the likelihood of developing dementia,” Elena Moro, MD, the study’s lead author, said in a press release...

Parkinson's

2020-07-09

Deep Brain Stimulation Not Linked to Greater Risk of Dementia for Parkinson’s Patients, Study Concludes
Melatonin Levels in Parkinson’s Patients May Be Linked to Non-motor Symptoms

Alterations in the levels of melatonin — the hormone that controls sleep-wake cycles — circulating in the blood are associated with certain non-motor symptoms of Parkinson’s disease, namely sleep disturbances, gastrointestinal issues, and heart problems.


The study with that finding, “Elevated Plasma Melatonin Levels Are Correlated With the Non-motor Symptoms in Parkinson’s Disease: A Cross-Sectional Study,” was published in the journal Frontiers in Neuroscience.


Melatonin is a hormone produced by the pineal gland, a small pea-shaped gland in the brain that regulates sleep. Higher levels of this hormone are usually present at night...

Parkinson's

2020-07-01

Melatonin Levels in Parkinson’s Patients May Be Linked to Non-motor Symptoms
Rice team makes tiny, magnetically powered neural stimulator

Rice University neuroengineers have created a tiny surgical implant that can electrically stimulate the brain and nervous system without using a battery or wired power supply.


The neural stimulator draws its power from magnetic energy and is about the size of a grain of rice. It is the first magnetically powered neural stimulator that produces the same kind of high-frequency signals as clinically approved, battery-powered implants that are used to treat epilepsy, Parkinson's disease, chronic pain and other conditions...

Parkinson's

2020-06-08

Rice team makes tiny, magnetically powered neural stimulator
Parkinson's Patient Improving After First-Ever Stem Cell Therapy

In a first, scientists have treated a Parkinson's disease patient with his own skin cells -- repurposing them to become key brain cells that the disease kills off.


Two years after receiving the experimental treatment, the patient has had no adverse effects, his doctors report. His symptoms, meanwhile, have either stabilized or gotten somewhat better.


"The improvement has been modest," said senior researcher Kwang-Soo Kim, who directs the molecular neurobiology laboratory at the Harvard-affiliated McLean Hospital, in Belmont, Mass...

Parkinson's

2020-05-13

Parkinson's Patient Improving After First-Ever Stem Cell Therapy
COVID-19 Presents Distinct Challenges, and Opportunities, with Parkinson’s

People with Parkinson’s disease can face “hidden sorrows” during the COVID-19 pandemic, like increased stress and limits on physical activity, that could worsen their symptoms. But ways exist to mitigate these “less visible” threats of social distancing and other changes in daily routines.


Indeed, the pandemic may facilitate wider access to helpful online resources, and could open new opportunities for research, two neurologists suggest...

Parkinson's

2020-04-08

COVID-19 Presents Distinct Challenges, and Opportunities, with Parkinson’s
Neupro Patches Effective in Parkinson’s, Real-world Study Shows

In a real-world clinical setting, Neupro Patches (rotigotine) eased the clinical signs and symptoms of Parkinson’s disease, with more than 70% of patients reporting mild improvement or better, including those 80 years and older, a real-world study shows.


No new or notable safety concerns were reported...

Parkinson's

2020-08-28

Neupro Patches Effective in Parkinson’s, Real-world Study Shows
Deep Brain Stimulation Found Helpful for Working-age Parkinson’s Patients

Working-age adults with Parkinson’s disease who received deep brain stimulation (DBS) showed better social and occupational functioning than those who received the best medical therapies alone, a study has found.


As such, the authors suggest, DBS could be prescribed to this Parkinson’s population to help preserve these aspects of their lives...

Parkinson's

2020-08-17

Deep Brain Stimulation Found Helpful for Working-age Parkinson’s Patients
DBS Eases Symptoms and May Slow Progression in Early Stage Patients, Study Says

When given to people at earlier stages of Parkinson’s disease, deep brain stimulation (DBS) reduces the complexity of their treatment, while safely providing long-term motor benefits and possibly slowing disease progression, data from a five-year pilot trial suggests.


A planned Phase 3 study has already received the go-ahead from the U.S. Food and Drug Administration (FDA). If these results are confirmed in a larger group of earlier stage patients, DBS will be the first therapy shown to be effective at slowing disease progression.


Findings were reported in the study, “Deep Brain Stimulation in Early-Stage Parkinson’s Disease: Five Year Outcomes,” published in the journal Neurology.

Parkinson's

2020-07-07

DBS Eases Symptoms and May Slow Progression in Early Stage Patients, Study Says
Newer MRI Approaches May Allow Tremor To Be Treated Without Surgery

New magnetic resonance imaging (MRI) techniques capable of zeroing in on a pea-size region of the brain responsible for movement control may allow physicians to treat patients with Parkinson’s disease or essential tremor without having to resort to invasive brain surgery.


These methods were described in the study, “Advanced MRI techniques for transcranial high intensity focused ultrasound targeting,” published in the journal Brain...

Parkinson's

2020-06-22

Newer MRI Approaches May Allow Tremor To Be Treated Without Surgery
Vercise DBS System Eases Parkinson’s Symptoms Over One Year, Trial Reports

Deep brain stimulation with Boston Scientific’s Vercise system led to sustained “on” periods without troublesome dyskinesia and improvements in both motor and non-motor symptoms of Parkinson’s disease for at least one year, updated findings from the INTREPID trial show.


Use of the Vercise Deep Brain Stimulation system in patients enrolled in this ongoing study was also found to be safe...

Parkinson's

2020-05-28

Vercise DBS System Eases Parkinson’s Symptoms Over One Year, Trial Reports
‘Keep On Moving’ Video Marks World Parkinson’s Day This Saturday

To heighten awareness of Parkinson’s disease (PD) and inspire patients and their families, Bial Pharmaceuticals has produced a short video to mark World Parkinson’s Day this Saturday, April 11.


Called “Keep On Moving,” the production also seeks to destigmatize the neurodegenerative disease and show the diversity and accomplishments of people living with Parkinson’s. It’s part of a global campaign that Bial, based in Portugal, launched four years ago...

Parkinson's

2020-04-10

‘Keep On Moving’ Video Marks World Parkinson’s Day This Saturday
Foliglurax Fails to Minimize Long-term Use Side Effects of Levodopa, Phase 2 Trial Shows

Despite being safe and well-tolerated, foliglurax (PTX002331), an investigational therapy for Parkinson’s disease, failed to significantly reduce some of the effects associated with long-term use of levodopa, including its “wearing-off” effect and motor complications, according to data from a Phase 2 clinical trial.


As a result, Lundbeck, the company that currently holds the therapy’s development and commercial rights, has decided to terminate its development program and to write-down foliglurax’s current value of €100 million (about $108 million)...

Parkinson's

2020-04-03

Foliglurax Fails to Minimize Long-term Use Side Effects of Levodopa, Phase 2 Trial Shows
Levodopa Improves Handwriting, Dexterity Tasks in Parkinson’s Patients, Study Indicates

Levodopa improved handwriting and dexterity tasks among people living with Parkinson’s disease, a recent study found.


The results, “Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson’s disease,” were published in the Journal of Neural Transmission.


Neurological examinations of Parkinson’s patients that seek to quantify motor function impairment can vary between different examiners and may make it a struggle to detect subtle changes...

Parkinson's

2020-08-27

Levodopa Improves Handwriting, Dexterity Tasks in Parkinson’s Patients, Study Indicates
New Insight May Unveil Ways to Lessen Side Effects of Deep Brain Stimulation in Parkinson’s Patients

Distinct connections between nerve cells in the brain may explain why some Parkinson’s disease patients develop impulsivity and behavioral problems after deep brain stimulation (DBS) therapy, according to a recent study.


These findings may help make DBS safer and more effective by adequately targeting the regions in the brain responsible for motor control.


The study, “The structural connectivity of subthalamic deep brain stimulation correlates with impulsivity in Parkinson’s,” was published in the journal Brain...

Parkinson's

2020-07-10

New Insight May Unveil Ways to Lessen Side Effects of Deep Brain Stimulation in Parkinson’s Patients
FDA Approves Medtronic’s Percept PC Deep Brain Stimulation System

The U.S. Food and Drug Administration (FDA) has approved the Percept PC Neurostimulator by Medtronic, designed to allow for a more individualized use of deep brain stimulation therapy in people with Parkinson’s disease and related disorders.


While this device is the fourth deep brain stimulation (DBS) system to be approved in the U.S., it is the first system able to sense and record brain signals while therapy is delivered. As such, it is expected to help doctors more precisely tailor treatment to a patient’s needs.


“Percept uses BrainSense technology, which captures brain signal data from implanted brain leads, combined with a patient diary system,” Joohi Jimenez-Shahed, MD, professor of neurology at Icahn School of Medicine at Mount Sinai, said in a news release by the Michael J. Fox Foundation...

Parkinson's

2020-07-02

FDA Approves Medtronic’s Percept PC Deep Brain Stimulation System
Nuplazid Shows Sustained Easing of Psychosis in Patients in Phase 3 Trial

Daily use of Nuplazid (pimavanserin) leads to strong and sustained reductions in the frequency and severity of hallucinations and delusions in people with Parkinson’s disease psychosis, according to data from a long-term extension study.


These findings, “Improvement and Durability in SAPS-PD Assessment over 10 Weeks of Pimavanserin Treatment for Parkinson’s Disease Psychosis,” were presented at the at the 2020 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, which was held virtually due to the COVID-19 pandemic...

Parkinson's

2020-06-08

Nuplazid Shows Sustained Easing of Psychosis in Patients in Phase 3 Trial
Link between diesel exhaust and risk of Parkinson’s discovered

Researchers have uncovered the process by which air pollution can damage brain cells, leading to an increased risk of Parkinson’s disease. Chemicals found in diesel fuel reduced autophagic flux, which is a major pathway implicated in neurodegeneration.


A new UCLA study in zebrafish has identified the process by which air pollution can damage brain cells, potentially contributing to Parkinson’s disease.


Published in the peer-reviewed journal Toxicological Sciences, the findings show that chemicals in diesel exhaust can trigger the toxic buildup of a protein in the brain called alpha-synuclein, which is commonly seen in people with the disease...

Parkinson's

2020-05-20

Link between diesel exhaust and risk of Parkinson’s discovered
$70 Million Raised for Neuron Replacement Therapy Techniques to Treat Parkinson’s

Aspen Neuroscience has raised $70 million to advance the development of  Parkinson’s disease therapies using patients’ own cells.


The products, ANPD001 and ANPD002, are the first-ever Parkinson’s treatments designed to use a patient’s own cells as a replacement to restore neuronal function and to modify disease progression. This approach is referred to as an autologous neuron replacement therapy...

Parkinson's

2020-04-08

$70 Million Raised for Neuron Replacement Therapy Techniques to Treat Parkinson’s
About Me

Hi, I'm Tom, from whose brain these Deep Brain Thoughts flow! Thank you for visiting my blog, and keep coming back to enjoy future ramblings!

See my full profile >

© 2020 by Deep Brain Thoughts. Proudly created with Wix.com

Last Updated: 2019-09-11

Connect With Me

  • Facebook
  • Twitter
  • RSS